Read by QxMD icon Read

Hematological Oncology

Jeffrey A Barnes, Robert Redd, David C Fisher, Ephraim P Hochberg, Tak Takvorian, Donna Neuberg, Eric Jacobsen, Jeremy S Abramson
This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycles 2 to 6. Patients without disease progression after 6 cycles continued panobinostat monotherapy for up to 6 additional cycles in the absence of disease progression. Eighteen eligible subjects were enrolled, and 18 were evaluable for response...
June 28, 2018: Hematological Oncology
Gabriela Vera-Lozada, Priscilla Segges, Claudio Gustavo Stefanoff, Mário Henrique M Barros, Gerald Niedobitek, Rocio Hassan
The search for clinically relevant molecular markers in classical Hodgkin lymphoma (cHL) is hampered by the histopathological complexity of the disease, resulting from the admixture of a small number of neoplastic Hodgkin and Reed-Sternberg (H-RS) cells with an abundant and heterogeneous microenvironment. In this study, we evaluated gene expression profiles of 11 selected genes previously proposed as a molecular score for adult cHL, aiming to validate its application in the pediatric setting. Assays were performed by RT-qPCR from formalin-fixed paraffin-embedded (FFPE) lymph nodes in 80 patients with cHL...
June 14, 2018: Hematological Oncology
Ayalew Tefferi
No abstract text is available yet for this article.
June 14, 2018: Hematological Oncology
Shuchao Qin, Lei Fan, Jinhua Liang, Robert Gale, Yi Miao, Yujie Wu, Rong Wang, Hui Yang, Wei Wu, Yi Xia, Jiazhu Wu, Huayuan Zhu, Li Wang, Wei Xu, Jianyong Li
Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese with CLL is unknown. We interrogated clinical and laboratory data from 334 newly diagnosed, untreated Chinese CLL without treatment indication upon diagnosis to identify variables associated with TTT and develop a prognostic score...
June 14, 2018: Hematological Oncology
Panagiotis Tsirigotis, Theodoros Vassilakopoulos, Ioannis Batsis, Zoi Bousiou, Konstantinos Gkirkas, Ioanna Sakellari, Panayotis Kaloyannidis, Paraskevi Roussou, Gerassimos A Pangalis, Maria Moschogiannis, George Vassilopoulos, Panagiotis Repousis, Aekaterini Megalakaki, Eurydiki Michalis, Christina Kalpadakis, Helen A Papadaki, Ioannis Kotsianidis, Eleftheria Hatzimichael, Alexandros Spyridonidis, Konstantinos Anargyrou, Elias Poulakidas, Panagiota Giannoullia, Ioannis Apostolidis, Maria Stamouli, Konstantinos Konstantopoulos, Vassiliki Pappa, Panayiotis Panayiotidis, Nikolaos Harhalakis, Achilles Anagnostopoulos, Maria Angelopoulou
The outcome of patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after autologous stem cell transplantation (auto-SCT) is poor. Recently, the anti-CD30 monoclonal antibody-drug conjugate, brentuximab vedotin (BV), has shown remarkable activity in the setting of R/R cHL. In the pivotal phase II study, BV produced an overall response rate of 75% and a median progression-free survival of 6.7 months. Although these results have been reproduced by large registry studies, the impact of BV on the overall survival (OS) of patients with R/R cHL has not been addressed so far...
June 8, 2018: Hematological Oncology
Takeshi Hara, Takeshi Yoshikawa, Hideko Goto, Michio Sawada, Toshiki Yamada, Kenji Fukuno, Senji Kasahara, Yuhei Shibata, Takuro Matsumoto, Ryoko Mabuchi, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Nobuhiro Kanemura, Yasuhito Nannya, Naoki Katsumura, Takeshi Takahashi, Yusuke Kito, Tsuyoshi Takami, Tatsuhiko Miyazaki, Tamotsu Takeuchi, Masahito Shimizu, Hisashi Tsurumi
Pirarubicin (tetrahydropyranyl adriamycin [THP]) is an anthracyclin with less cardiotoxicity than doxorubicin (DOX). We previously reported the efficacy and safety of R-THP-COP consisting of rituximab (R), THP, cyclophosphamide (CPA), vincristine (VCR), and prednisolone (PSL) for diffuse large B cell lymphoma (DLBCL) in phase 2 studies. Here, we prospectively compared the efficacy and safety of the R-THP-COP and standard R-CHOP regimen (consisting of R, CPA, DOX, VCR, and PSL) in a noninferiority phase 3 trial...
June 8, 2018: Hematological Oncology
Francesca De Felice, Lavinia Grapulin, Alessandra Pieroni, Francesca Salerno, Gianna Maria D'Elia, Alessandro Pulsoni, Daniela Musio, Vincenzo Tombolini
No abstract text is available yet for this article.
June 3, 2018: Hematological Oncology
Carrie A Thompson, Kathleen J Yost, Matthew J Maurer, Cristine Allmer, Umar Farooq, Thomas M Habermann, David J Inwards, William R Macon, Brian K Link, Allison C Rosenthal, James R Cerhan
Our aim was to evaluate whether quality of life (QOL) scores at diagnosis predict survival among patients with aggressive lymphoma. Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis in the University of Iowa/Mayo Clinic SPORE and systematically followed for event-free and overall survival (OS). QOL was measured with the Functional Assessment of Cancer Treatment-General (FACT-G), which measures 4 domains: physical, social/family, emotional, and functional well-being (WB); a single item Linear Analogue Self-Assessment (LASA) measuring overall QOL; and a spiritual WB LASA...
June 3, 2018: Hematological Oncology
Alexandra Junge, Ulrike Bacher, Beatrice U Mueller, Peter Keller, Max Solenthaler, Thomas Pabst
Natural killer cells mediate antibody-dependent cell-mediated cytotoxicity, and CD16 exerts key functions to induce antibody-dependent cell-mediated cytotoxicity response. Because the prognostic relevance of aberrant CD16 expression in AML patients at diagnosis is unknown, we analyzed 325 AML patients undergoing intensive chemotherapy for aberrant CD16+ and CD56+ natural killer-cell marker expression. CD56+ AML patients had inferior median event-free (EFS; P = 0.0699) and overall survival (OS; 10.9 versus 20...
June 3, 2018: Hematological Oncology
Yinjun Lou, Ying Lu, Zhijuan Zhu, Yafang Ma, Shanshan Suo, Yungui Wang, Dong Chen, Hongyan Tong, Wenbin Qian, Haitao Meng, Wenyuan Mai, Wenjun Yu, Weilai Xu, Lei Wang, Liping Mao, Renzhi Pei, Jie Jin
Limited data was available for long-term follow-up in newly diagnosed acute promyelocytic leukemia (APL) patients treated with all-trans-retinoic acid (ATRA) plus intravenously arsenic trioxide (ATO)-based front-line therapy. The aim of this work was to retrospectively analyze the long-term survival rate and frequency of therapy-related myeloid neoplasia (t-MN) occurring in a large cohort of APL patients. A total of 760 newly diagnosed patients with APL between January 1999 and May 2016 were evaluated. The early death rate was 9...
June 3, 2018: Hematological Oncology
Alina Klein, Aaron Polliack, Anat Gafter-Gvili
Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin lymphoma (HL) and non-HL than the general population. Non-Hodgkin lymphoma is more common than HL in these patients, and diffuse large B cell lymphoma is the most frequent subtype observed. Although the clinical course of lymphoma in RA is often aggressive, the prognosis in these cases is similar to that of lymphoma in the general population. In this review, we summarize data derived from both retrospective and prospective studies, regarding incidence, pathogenesis, and outcome of lymphomas in RA patients and outline the possible mechanisms and hypotheses linking these 2 disorders...
June 3, 2018: Hematological Oncology
Lauriane Filliatre-Clement, Delphine Maucort-Boulch, Estelle Bourbon, Lionel Karlin, Violaine Safar, Emmanuel Bachy, Pierre Sesques, Emmanuelle Ferrant, Fadela Bouafia, Anne Lazareth, Dana Ghergus, Bertrand Coiffier, Alexandra Traverse Glehen, Gilles Salles, Hervé Ghesquieres, Clémentine Sarkozy
In the rituximab era, one-third of diffuse large B-cell lymphoma patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy. Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. We performed a retrospective analysis, which included 104 diffuse large B-cell lymphoma patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease...
May 2, 2018: Hematological Oncology
Neil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, Rena Buckstein, Eugenia Piliotis, Kevin R Imrie, Lisa Chodirker, Mary-Anne Cussen, Ellen Miles, Marciano D Reis, Zeina Ghorab, Matthew C Cheung
Five-year overall survival for high-risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an exploratory phase II trial of intensified treatment for patients with intermediate and high-risk follicular lymphoma. Front-line treatment with chemo-immunotherapy consisting of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone was followed by radio- immunotherapy with 90-Yttrium ibritumomab tiuxetan consolidation, and 2 years of rituximab maintenance...
April 30, 2018: Hematological Oncology
Naveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, Kevin J Freise
Progression-free survival (PFS) is the standard endpoint for demonstration of clinical effectiveness of novel therapies in relapsed or refractory multiple myeloma (RRMM). However, the long evaluation times for PFS limits its usefulness in the development of new therapies. Therefore, the objective of this analysis was to determine the relationship between response rates and median PFS in RRMM. A database was systematically developed from 268 identified RRMM trials reported from 1999 to 2016. Evaluated covariates for the relationship between response rates and PFS included age, sex, drug class(es), and number of drug classes...
April 19, 2018: Hematological Oncology
Camille Debord, Nelly Robillard, Olivier Theisen, Thomas Gastinne, Pascal Godmer, Julie Graveleau, Steven Le Gouill, Odile Luycx, Mourad Tiab, Marion Loirat, Elsa Lestang, Soraya Wuillème, Catherine Godon, Marion Eveillard, Marie Christine Béné
No abstract text is available yet for this article.
April 15, 2018: Hematological Oncology
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, Elisabetta Abruzzese, Giulia Benevolo, Micaela Bergamaschi, Alessia Tieghi, Massimiliano Bonifacio, Massimo Breccia, Lucia Catani, Mario Tiribelli, Mariella D'Adda, Nicola Sgherza, Alessandro Isidori, Francesco Cavazzini, Bruno Martino, Roberto Latagliata, Monica Crugnola, Florian Heidel, Costanza Bosi, Adalberto Ibatici, Francesco Soci, Domenico Penna, Luigi Scaffidi, Franco Aversa, Roberto M Lemoli, Umberto Vitolo, Antonio Cuneo, Domenico Russo, Michele Cavo, Nicola Vianelli, Francesca Palandri
Infections represent one of the major concerns regarding the utilization of ruxolitinib (RUX) in patients with myelofibrosis. With the aim to investigate epidemiology, outcome and risk factors for infections in RUX-exposed patients, we collected clinical and laboratory data of 446 myelofibrosis patients treated with RUX between June 2011 and November 2016 in 23 European Hematology Centers. After a median RUX exposure of 23.5 months (range, 1-56), 123 patients (28%) experienced 161 infectious events (grades 3-4 32%, fatal 9%), for an incidence rate of 17 cases per 100 pts/y...
April 6, 2018: Hematological Oncology
Geffen Kleinstern, Mor Averbuch, Rania Abu Seir, Riki Perlman, Dina Ben Yehuda, Ora Paltiel
Although autoimmune diseases (AIDs) are known to predispose to non-Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B-cell NHL onset by comparing AID history (determined by self-report and medication review and supplemented by chart review where possible) among 435 adult B-NHL patients in Hadassah-Hebrew University Medical Center, diagnosed 2009-2014, and 414 age-and-sex frequency-matched controls. We examined AIDs as a whole, B- and T-cell-mediated AIDs, and autoimmune thyroid diseases...
April 2018: Hematological Oncology
Rachele Ciccocioppo, Giorgio A Croci, Federico Biagi, Alessandro Vanoli, Costanza Alvisi, Giorgio Cavenaghi, Roberta Riboni, Mariarosa Arra, Paolo G Gobbi, Marco Paulli, Gino R Corazza
Enteropathy-associated T-cell lymphoma is regarded as a dismal, late complication of coeliac disease, though a single case of T-cell lymphoma with such features arising in the setting of autoimmune enteropathy of the adult has been reported to date. We aim to describe the case of a 41-year-old woman complaining of severe malabsorption syndrome, who was diagnosed with autoimmune enteropathy based on the presence of flat intestinal mucosa unresponsive to any dietary restriction and positivity for enterocyte autoantibodies...
April 2018: Hematological Oncology
Maria-Victoria Mateos, Hartmut Goldschmidt, Jesus San-Miguel, Joseph Mikhael, Lucy DeCosta, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, Xavier Leleu
We performed analyses of the randomized phase 3 ASPIRE and ENDEAVOR trials to investigate the efficacy of carfilzomib among subgroups of relapsed or refractory multiple myeloma patients who had early or late disease relapse following initiation of the immediately prior therapy. In ASPIRE and ENDEAVOR, patients had received 1 to 3 prior lines of therapy. Patients in ASPIRE received carfilzomib, lenalidomide, and dexamethasone (KRd) or lenalidomide and dexamethasone (Rd), and patients in ENDEAVOR received carfilzomib and dexamethasone (Kd) or bortezomib and dexamethasone (Vd)...
April 2018: Hematological Oncology
Takaaki Konuma, Chisato Kohara, Eri Watanabe, Motoko Mizukami, Etsuko Nagai, Susumu Tanoue, Masamichi Isobe, Koji Jimbo, Seiko Kato, Nobuhiro Ohno, Satoshi Takahashi, Arinobu Tojo
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are effective agents in the treatment of Philadelphia chromosome-positive leukemia. However, vascular events have developed in some patients receiving each TKI. The perturbation of circulating monocyte subsets and their expressions of chemokine and scavenger receptors are associated with the development of cardiovascular events. Here, we examined the subsets of circulating monocytes and their phenotypes in 51 patients treated with imatinib, nilotinib, and dasatinib, and 11 healthy subjects in our institute...
April 2018: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"